DE69634416T2 - Chinolin-derivate - Google Patents

Chinolin-derivate Download PDF

Info

Publication number
DE69634416T2
DE69634416T2 DE69634416T DE69634416T DE69634416T2 DE 69634416 T2 DE69634416 T2 DE 69634416T2 DE 69634416 T DE69634416 T DE 69634416T DE 69634416 T DE69634416 T DE 69634416T DE 69634416 T2 DE69634416 T2 DE 69634416T2
Authority
DE
Germany
Prior art keywords
compound
formula
pharmaceutically acceptable
alkyl
ring
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69634416T
Other languages
German (de)
English (en)
Other versions
DE69634416D1 (de
Inventor
Giuseppe Arnaldo Maria Giardina
Mario Grugni
Luca Francesco Raveglia
Carlo Farino
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline SpA
Original Assignee
GlaxoSmithKline SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from IT95MI002461 external-priority patent/IT1276170B1/it
Priority claimed from IT96MI001689 external-priority patent/IT1307331B1/it
Application filed by GlaxoSmithKline SpA filed Critical GlaxoSmithKline SpA
Application granted granted Critical
Publication of DE69634416D1 publication Critical patent/DE69634416D1/de
Publication of DE69634416T2 publication Critical patent/DE69634416T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/50—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4
    • C07D215/52—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4 with aryl radicals attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pulmonology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE69634416T 1995-11-24 1996-11-22 Chinolin-derivate Expired - Fee Related DE69634416T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
ITMI952461 1995-11-24
IT95MI002461 IT1276170B1 (it) 1995-11-24 1995-11-24 Derivati chinolinici
IT96MI001689 IT1307331B1 (it) 1996-08-02 1996-08-02 Derivati chinolinici
ITMI961689 1996-08-02
PCT/EP1996/005203 WO1997021680A1 (en) 1995-11-24 1996-11-22 Quinoline derivatives

Publications (2)

Publication Number Publication Date
DE69634416D1 DE69634416D1 (de) 2005-04-07
DE69634416T2 true DE69634416T2 (de) 2005-12-29

Family

ID=26331326

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69634416T Expired - Fee Related DE69634416T2 (de) 1995-11-24 1996-11-22 Chinolin-derivate

Country Status (26)

Country Link
US (1) US6277862B1 (enExample)
EP (1) EP0876347B1 (enExample)
JP (1) JP2000501104A (enExample)
KR (1) KR19990071597A (enExample)
CN (1) CN1207730A (enExample)
AP (1) AP9801237A0 (enExample)
AR (1) AR004972A1 (enExample)
AT (1) ATE289994T1 (enExample)
BG (1) BG102558A (enExample)
BR (1) BR9611820A (enExample)
CA (1) CA2238298A1 (enExample)
CZ (1) CZ157998A3 (enExample)
DE (1) DE69634416T2 (enExample)
EA (1) EA002124B1 (enExample)
ES (1) ES2236757T3 (enExample)
IL (1) IL124522A0 (enExample)
MX (1) MX9804107A (enExample)
NO (1) NO311212B1 (enExample)
NZ (1) NZ323387A (enExample)
OA (1) OA11010A (enExample)
PL (1) PL326967A1 (enExample)
SK (1) SK66798A3 (enExample)
TR (1) TR199800924T2 (enExample)
TW (1) TW353066B (enExample)
UY (1) UY24733A1 (enExample)
WO (1) WO1997021680A1 (enExample)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL170837B1 (pl) 1991-10-18 1997-01-31 Monsanto Co S rod ek g r zybobó j c zy PL PL PL PL PL PL
SE9703407D0 (sv) * 1997-09-19 1997-09-19 Astra Ab New use
SE9802073D0 (sv) 1998-06-11 1998-06-11 Astra Ab New use
GB9825554D0 (en) 1998-11-20 1999-01-13 Smithkline Beecham Spa Novel Compounds
US7037922B1 (en) * 2000-03-10 2006-05-02 Neurogen Corporation Aryl fused 2,4-disubstituted pyridines: NK3 receptor ligands
AU4038000A (en) 1999-03-29 2000-10-16 Neurogen Corporation 4-substituted quinoline derivatives as gaba receptor ligands
WO2000064877A1 (en) 1999-04-26 2000-11-02 Neurogen Corporation 2-aminoquinolinecarboxamides: neurokinin receptor ligands
DE60209362T2 (de) * 2001-04-11 2006-10-26 Glaxosmithkline S.P.A. 3-substituierte chinolin-4-carbonsäureamidderivate als nk-3- und nk-2-rezeptorantagonisten
AU2002259147A1 (en) * 2001-05-08 2002-11-18 Schering Corporation Use of neurokinin receptor antagonists to treat androgen-dependent diseases
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
EP1911763B1 (en) 2003-01-28 2010-08-11 Ironwood Pharmaceuticals, Inc. Compositions for the treatment of gastrointestinal disorders
GB0303086D0 (en) * 2003-02-11 2003-03-19 Merck Sharp & Dohme New compounds
GB0419192D0 (en) 2004-08-27 2004-09-29 Merck Sharp & Dohme Therapeutic agents
SG155229A1 (en) * 2004-11-09 2009-09-30 Smithkline Beecham Corp Glycogen phosphorylase inhibitor compounds and pharmaceutical compositions thereof
GB0425077D0 (en) * 2004-11-12 2004-12-15 Smithkline Beecham Corp Novel compounds
GB0515580D0 (en) 2005-07-29 2005-09-07 Merck Sharp & Dohme Therapeutic compounds
EP1915361A1 (en) * 2005-08-11 2008-04-30 AstraZeneca AB Alkylpyridyl quinolines as nk3 receptor modulators
AR057130A1 (es) 2005-09-21 2007-11-14 Astrazeneca Ab Quinolinas de alquilsulfoxido y una composicion farmaceutica
TW200804288A (en) * 2005-12-12 2008-01-16 Astrazeneca Ab Alkylsulphonamide quinolines
MX354786B (es) 2007-06-04 2018-03-21 Synergy Pharmaceuticals Inc Agonistas de guanilato ciclasa utiles para el tratamiento de trastornos gastrointestinales, inflamacion, cancer y otros trastornos.
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
KR20100087300A (ko) * 2007-09-28 2010-08-04 글락소스미스클라인 엘엘씨 글리코겐 포스포릴라아제 억제제 화합물 및 이의 약학적 조성물
CN101861303A (zh) * 2007-09-28 2010-10-13 葛兰素史密丝克莱恩有限责任公司 糖原磷酸化酶抑制剂化合物和其药物组合物
ES2522968T3 (es) 2008-06-04 2014-11-19 Synergy Pharmaceuticals Inc. Agonistas de guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
AU2009270833B2 (en) 2008-07-16 2015-02-19 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
WO2018129556A1 (en) 2017-01-09 2018-07-12 Ardelyx, Inc. Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
MX381407B (es) 2008-12-31 2025-03-12 Ardelyx Inc Compuestos y métodos para inhibir el antiporte mediado por intercambiador de iones de sodio/iones de hidrógeno (nhe) en el tratamiento de trastornos asociados con retención de fluido o sobrecarga de sal y trastornos del tracto gastrointestinal.
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
US10376481B2 (en) 2012-08-21 2019-08-13 Ardelyx, Inc. Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
MX366293B (es) 2012-08-21 2019-07-04 Ardelyx Inc Compuestos y metodos para inhibir al antipuerto mediado por nhe en el tratamiento de trastornos asociados con la retencion de fluidos o la sobrecarga de sal y trastornos del tracto gastrointestinal.
AU2014235209B2 (en) 2013-03-15 2018-06-14 Bausch Health Ireland Limited Guanylate cyclase receptor agonists combined with other drugs
AU2014235215A1 (en) 2013-03-15 2015-10-01 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
HRP20191000T1 (hr) 2013-04-12 2019-09-20 Ardelyx, Inc. Spojevi za vezanje nhe3 i metode inhibiranja transporta fosfata
WO2014170648A1 (en) 2013-04-19 2014-10-23 Astrazeneca Ab A nk3 receptor antagonist compound (nk3ra) for use in a method for the treatment of polycystic ovary syndrome (pcos)
BR112015030326A2 (pt) 2013-06-05 2017-08-29 Synergy Pharmaceuticals Inc Agonistas ultrapuros de guanilato ciclase c, método de fabricar e usar os mesmos
WO2017072629A1 (en) 2015-10-29 2017-05-04 Cadila Healthcare Limited Pharmaceutical combination of nk3 receptor antagonist and biguanides
MX395405B (es) 2017-01-09 2025-03-25 Ardelyx Inc Compuestos útiles para tratar trastornos del tracto gastrointestinal.
MX2019008171A (es) 2017-01-09 2020-02-05 Ardelyx Inc Inhibidores del antiporte mediado por nhe.

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2538388B1 (fr) * 1982-12-24 1985-06-21 Pharmuka Lab Nouveaux derives de naphtalene- ou azanaphtalenecarboxamide, leurs procedes de preparation et leur utilisation comme medicaments
JPS63119455A (ja) * 1986-06-27 1988-05-24 Nippon Shinyaku Co Ltd グリシン誘導体
SK282721B6 (sk) * 1994-05-27 2002-11-06 Smithkline Beecham S.P.A. Nepeptidové NK3 antagonistické látky, spôsob ich výroby, farmaceutické prostriedky s ich obsahom a ich použitie
IT1270615B (it) * 1994-07-14 1997-05-07 Smithkline Beecham Farma Uso di derivati di chinolina

Also Published As

Publication number Publication date
NO311212B1 (no) 2001-10-29
PL326967A1 (en) 1998-11-09
BG102558A (bg) 1999-03-31
EP0876347B1 (en) 2005-03-02
KR19990071597A (ko) 1999-09-27
CN1207730A (zh) 1999-02-10
SK66798A3 (en) 1999-01-11
OA11010A (en) 2003-03-06
WO1997021680A1 (en) 1997-06-19
IL124522A0 (en) 1998-12-06
JP2000501104A (ja) 2000-02-02
EP0876347A1 (en) 1998-11-11
TW353066B (en) 1999-02-21
NO982331D0 (no) 1998-05-22
MX9804107A (es) 1998-09-30
NZ323387A (en) 2000-02-28
AP9801237A0 (en) 1998-06-30
CA2238298A1 (en) 1997-06-19
ATE289994T1 (de) 2005-03-15
BR9611820A (pt) 1999-07-13
NO982331L (no) 1998-07-22
CZ157998A3 (cs) 1998-12-16
US6277862B1 (en) 2001-08-21
ES2236757T3 (es) 2005-07-16
EA002124B1 (ru) 2001-12-24
EA199800477A1 (ru) 1998-12-24
UY24733A1 (es) 2001-08-27
AR004972A1 (es) 1999-04-07
TR199800924T2 (xx) 1998-08-21
DE69634416D1 (de) 2005-04-07

Similar Documents

Publication Publication Date Title
DE69634416T2 (de) Chinolin-derivate
DE69628334T2 (de) Chinolin derivate als nk3 antagoniste
DE69533408T2 (de) Chinolinderivate als Tachykinin NK3 Rezeptor Antagonisten
DE69425662T2 (de) Als heilmittel nutzbare piperazin verbindungen
DE69816290T2 (de) Chinolin-4-carboxamidderivate als nk-2 und nk-3 rezeptor antagonisten
DE602005003128T2 (de) Chinazolinon-derivate als vanilloid-antagonisten
DE3877406T2 (de) Benzothiazolinon-derivate, ihre herstellung und pharmazeutische zusammensetzung.
DE602004005016T2 (de) Biphenylcarboxamidderivate und ihre verwendung als p38 kinase inhibitoren
WO1997021680A9 (en) Quinoline derivatives
DE2011806C3 (de) Tricyclische Verbindungen, Verfahren zu deren Herstellung und diese enthaltende pharmazeutische Zubereitungen
DE60209362T2 (de) 3-substituierte chinolin-4-carbonsäureamidderivate als nk-3- und nk-2-rezeptorantagonisten
DE69626416T2 (de) Salze von chinolinderivaten als nk3 antagonisten
JPH08169884A (ja) シクロプロパクロメンカルボン酸誘導体
DE69934514T2 (de) Chinolinderivate als nk-2 und nk-3 rezeptor-liganden
DE68905845T2 (de) Tetrazolverbindungen als antagonisten der excitatorischen aminosaeurerezeptoren.
DE602005004039T2 (de) Nicht-peptidische bradykinin-antagonisten und pharmazeutische zusammensetzungen daraus
DE69824582T2 (de) Neuartige Chinolin- und Naphthalincarboxamide, pharmazeutische Zusammensetzungen und Verfahren zum Inhibieren von Calpain
DE60015732T2 (de) Amidverbindungen zur stärkung der cholinergischen wirkung
DE69920516T2 (de) Substituierte oxime und hydrazone als neurokinin antagonisten
DE3813531A1 (de) Neue 2-aminoalkyl-4-benzyl-1-(2h)-phthalazinon-derivate
EP1335720A1 (de) Sulfonamiden zur behandlung von erkrankungen des zentralen nervensystems
DE69826881T2 (de) Neue indolcarboxamide, pharmazeutische zusammensetzungen und methoden zur hemmung von calpain
DE69210229T2 (de) Dihydrochinolin NMDA Antagonisten
WO2012001438A1 (en) Use of kynurenic acid amide derivatives for the treatment of huntington's disease
AU757836B2 (en) Quinoline derivatives

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee